Free ToolRuns in browser

Semaglutide Half-Life Calculator

Semaglutide has a pharmacokinetic half-life of approximately 168 hours (7 days) — the longest of any approved GLP-1 receptor agonist. This exceptionally long half-life is what makes once-weekly dosing practical and enables the drug to maintain near-steady plasma concentrations between injections. The visualizer models how drug concentration builds across multiple injection cycles and shows how long meaningful drug levels persist after the final dose.

Interactive tool

Half-Life Visualizer

The visualizer runs entirely in your browser — no account required. Select Semaglutide in the compound dropdown to model your schedule.

What You Enter

  • Starting dose (0.25 mg, 0.5 mg, 1 mg, or 2.4 mg)
  • Number of weeks to model (1–24)
  • Day of week for injection

What You Get

  • Week-by-week plasma concentration curve
  • Estimated time to steady-state (approximately 4–5 weeks of weekly dosing)
  • Projected clearance date after final dose
  • Annotation showing steady-state band
Reviewed: 2026-04-13Sources: 3Treatment: semaglutide

From calculator to tracker

The half-life visualizer feeds directly into the PeptideScholar dose tracker, which lets you log actual injection dates and overlay them against the pharmacokinetic model. The tracker also sends optional refill reminders calibrated to your dose schedule.

Frequently Asked Questions

Frequently Asked Questions

This tool and content are for informational purposes only. Pharmacokinetic estimates are based on published FDA-label population data and do not account for individual variation in renal function, body composition, or co-medications. Do not use this tool to make clinical decisions without consulting your prescribing physician.

Sources

  1. 1. Wegovy (semaglutide) Prescribing Information — Clinical Pharmacology
    FDA / Novo Nordisk • 2023
    Claim type: clinical
    View source →
  2. 2. Ozempic (semaglutide) Prescribing Information — Clinical Pharmacology
    FDA / Novo Nordisk • 2023
    Claim type: clinical
    View source →
  3. 3. Clinical Pharmacokinetics and Pharmacodynamics of Semaglutide
    Clinical Pharmacokinetics • 2021
    Claim type: clinical
    View source →

Medical Disclaimer

This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.

Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.

No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.